Summary.
A randomized controlled trial of the antifibrinolytic agent amino‐methylcyclohexane carboxylic acid (AMCA, Tranexamic acid) in the prophylactic treatment of haemophilia is reported. The active treatment (2 g daily) or indistinguishable inert tablets were given for 12 consecutive periods of 28 days. The effect of the active treatment was minimal and incapacity from the disease and the need for the administration of factor VIII were not reduced. It is considered that sound evidence does not exist for recommending the prophylactic use of antifibrinolytic drugs in haemophilia.
nor Strauss, Kevy, and Diamond (1965) could confirm an effect with epsilon-aminocaproic acid. We therefore conducted a double-blind trial with tranexamic acid (AMCA), 2 g per day, in 15 severe haemophiliacs aged 17 to 46 years, lasting one year. Placebo or active sugar-coated tablets were given for periods of 28 days, being randomly allocated by a Latin square design. The original design, for 12 patients, could not be completely followed, but eventually 68 periods, comprising 1 887 patientdays, were observed on the placebo and 70 periods, comprising 1 939 days on active tablets. Other treatment was as usual. The patients kept records on specially designed diary sheets. The results were analysed for site, frequency,
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.